



Negative electroretinograms: genetic and acquired causes,
diagnostic approaches and physiological insights
Xiaofan Jiang1,2,3 ● Omar A. Mahroo 1,2,3,4
Received: 15 March 2021 / Revised: 5 May 2021 / Accepted: 10 May 2021 / Published online: 14 June 2021
© The Author(s) 2021. This article is published with open access
Abstract
The dark-adapted human electroretinogram (ERG) response to a standard bright flash includes a negative-going a-wave
followed by a positive-going b-wave that crosses the baseline. An electronegative waveform (or negative ERG) results when
the b-wave is selectively reduced such that the ERG fails to cross the baseline following the a-wave. In the context of a
normally sized a-wave, it indicates a site of retinal dysfunction occurring after phototransduction (commonly at the
photoreceptor to bipolar cell synapse). This is an important finding. In genetic disease, the pattern of ERG abnormality can
point to variants in a small group of genes (frequently those associated with congenital stationary night blindness and
X-linked retinoschisis, but negative ERGs can also be seen in other conditions including syndromic disease). In acquired
disease, there are numerous causes, but specific features may point to melanoma-associated retinopathy (MAR). In some
cases, the visual symptoms precede the diagnosis of the melanoma and so the ERG findings can initiate investigations
facilitating early detection and treatment. Negative ERGs can occur in other paraneoplastic conditions, and in a range of
other diseases. This review will outline the physiological basis for the negative ERG, report prevalences in the literature from
different cohorts, discuss the range of causes, displaying examples of a number of ERG phenotypes, highlight features of a
clinical approach to patients, and briefly discuss further insights relating to current flows shaping the a-wave trough and from
single-cell transcriptome analysis.
Introduction
The dark-adapted human electroretinogram (ERG) response
to full-field flashes of a range of stimulus strengths includes
an initial negative-going component, the a-wave, followed
by a positive-going component, the b-wave. The a-wave
arises largely from hyperpolarisation of the photoreceptors
in response to the flash stimulus, and the b-wave arises
largely from depolarisation of ON bipolar cells (which
occurs in response to the reduction in glutamate release
at the photoreceptor to bipolar cell synapse). A-wave
amplitudes are measured from baseline to the negative
a-wave trough; b-wave amplitudes are conventionally
measured from the a-wave trough to the peak of the b-wave
(Fig. 1).
In response to most commonly used flash stimuli, the b-
wave is larger than the a-wave in healthy individuals:
this includes the DA 3 and DA 10 stimuli of the current
International Society for Clinical Electrophysiology of
Vision (ISCEV) standard protocol [1, 2] as well as the LA
3 stimulus; the DA 0.01 dim flash elicits a b-wave usually
with a minimally detectable a-wave. If the b-wave is smaller
than the a-wave, this is termed a negative ERG or an
electronegative waveform (Fig. 1), and, if present in
response to standard stimuli, indicates pathology [3]. This
might occur in response to flashes delivered in the dark-
adapted or light-adapted state, but much of this review will
focus on conditions in which negative ERGs are recorded in
the dark-adapted state to the standard 3 and 10 cd m−2 s
white flash stimuli (DA 3 and DA 10).
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The finding of a negative ERG is significant and guides
the differential diagnosis considerably [3]. In genetic condi-
tions, negative ERGs can narrow the list of genes likely to be
associated with the disease. In acquired conditions, a nega-
tive ERG can result from an inflammatory, or autoimmune
(including paraneoplastic), aetiology. Melanoma-associated
retinopathy (MAR) exhibits a negative ERG phenotype often
indistinguishable from that seen in complete congenital sta-
tionary night blindness (CSNB) [4], and the retinopathy can,
in some cases, precede the detection of the melanoma.
Tables 1 and 2 summarise genetic and acquired causes of
negative ERGs.
This review will discuss the physiological basis for the
negative ERG, and then report prevalence in various pub-
lished patient cohorts [5–8]. Genetic causes will then be
considered, along with the proportions of families with
disease associated with each of the main genes from a large
genetically characterised UK-based inherited retinal disease
cohort [9], together with illustrations of some key ERG
phenotypes. A range of acquired causes will subsequently
be presented, followed by features of a clinical approach to
patients in view of the range of causes and diagnostic fea-
tures. The additional value of ON–OFF ERGs [10] will be
introduced and briefly discussed. Some further insights will
be considered relating to current flows shaping the a-wave
trough [11], findings from single-cell transcriptome data
[12] and future treatments, before some final concluding
remarks.
Physiological basis
Phototransduction occurs in the outer segments of the rod
and cone photoreceptors. In darkness, photoreceptors are
depolarised by an inward current of cations entering
through channels in the outer segment membrane. These are
cyclic nucleotide-gated channels; they remain open when
bound by cyclic guanosine monophosphate (cGMP). Pho-
tons of light bring about isomerisation of the chromophore
(11-cis-retinal is converted to all-trans-retinal), and a cas-
cade of molecular reactions culminate in the depletion of
cGMP, which leads to closure of the cation channels and
consequent hyperpolarisation of the photoreceptor, that
is the cell membrane potential becomes more negative.
(The reader is referred to the review of Arshavsky et al. for
a detailed description of phototransduction) [13]. This
hyperpolarisation contributes to the ERG a-wave [14].
Photoreceptor hyperpolarisation leads to a reduction in
release of the neurotransmitter glutamate at the photo-
receptor to bipolar cell synapse. Rods (which constitute the
vast majority of photoreceptors in the human eye) synapse
with ON bipolar cells. These cells depolarise (their mem-
brane potential becomes less negative, or more positive) in
response to the light-induced reduction in photoreceptor
glutatamate release [15]. This depolarisation generates
much of the b-wave of the dark-adapted flash ERG. Cone
photoreceptors synapse with both ON and OFF bipolar
cells. The latter hyperpolarise in response to the light-
induced reduction in photoreceptor glutamate release. The
hyperpolarisation of these cells contribute to the cone sys-
tem a-wave [14], and their recovery also shapes the cone-
driven b-wave (together with the depolarising responses
from the cone-driven ON bipolar cells).
When phototransduction occurs normally in rod photo-
receptors, the dark-adapted a-wave is largely intact. Any
disruption of processes after phototransduction, such as
those affecting synaptic transmission or affecting the gen-
eration of the ON bipolar cell response, will selectively
impair the b-wave, thus potentially resulting in a negative
ERG. The genes CACNA1F and CABP4 encode proteins
expressed in the photoreceptor synapse involved in synaptic
transmission, and so pathogenic variants result in a negative
dark-adapted ERG [16]. The light-adapted (cone-driven)
ERG is affected by the impairment of transmission to both
ON and OFF bipolar cells. The genes NYX, TRPM1, LRIT3,
GRM6, and GPR179 encode proteins specifically involved
in bringing about ON bipolar cell depolarisation; thus
pathogenic variants again result in a negative dark-adapted
ERG, but the light-adapted ERG exhibits a shape reflective
of loss of ON bipolar cell, but intact OFF bipolar cell,
contributions [16]. Figure 2 illustrates schematically chan-
ges in the light-adapted cone-driven flash ERG in these
conditions. MAR gives a similar electrophysiological phe-
notype due to circulating autoantibodies to the TRPM1
protein expressed by ON bipolar cells [17].
Other mechanisms of disruption of post-phototransduction
processes exist, including genetic, inflammatory, toxic and
vascular. Due to the dual vascular supply of the retina (inner
layers supplied by the central retinal artery and drained by the
central retinal vein; outer layers (photoreceptors) supplied by
Fig. 1 Schematic of a normal (left panel) and electronegative (right
panel) DA 10 ERG response. The a-wave amplitude is measured
from baseline to a-wave trough, whilst the b-wave amplitude is mea-
sured from a-wave trough to b-wave peak. A negative ERG emerges
when the b-wave is smaller than the a-wave.
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the choroidal circulation), a central retinal artery or ischaemic
CRVO will selectively affect inner retinal responses,
leaving phototransduction intact, resulting in a negative
waveform. Certain neurodegenerative disorders, by affecting
bipolar cells earlier than photoreceptors, can also result in
negative ERGs.
When the dark-adapted flash a-wave is significantly
reduced, this indicates impairment of rod phototransduc-
tion. A negative ERG in this situation might in some
conditions indicate additional (post-phototransduction)
inner retinal disruption. In conditions where there is near
abolition of rod photoreceptor light responses, the dark-
adapted ERG reflects predominately the response of the
dark-adapted cone system [18]. In some individuals, the
dark-adapted cone system response to standard strength
bright flashes is negative (i.e. the cone-driven b-wave in
the dark is smaller than the cone-driven a-wave), but this is
not usually observed in healthy individuals in the dark
due to the simultaneously occurring, larger rod system
response. It is a characteristic of cone system responses
that, as flash strength increases, the a-wave amplitude
increases, whilst the b-wave increases to a maximum, and
then falls with further increases in flash strength (termed
the “photopic hill”) [19]. The underlying mechanisms
relate to changes in magnitude and kinetics of ON and
OFF pathway signals [20]. With brighter flashes, the b-
wave is smaller than the a-wave, yielding a negative
waveform. When rod responses are highly attenuated, for
example due to lack of available chromophore in Vitamin
A deficiency or RDH5-associated retinopathy (fundus
albipunctatus), or loss of rod sensitivity due to impaired
shut-off of activated rhodopsin in Oguchi disease,
the dark-adapted bright flash response may be negative,
largely reflecting an isolated cone system response. In
these cases, the a-wave is also significantly reduced
[18, 21], distinguishing these conditions from those which
primarily affect post-phototransduction signals.
Prevalence of negative electroretinograms
in patient cohorts
A negative dark-adapted response to standard stimuli is not
usually seen in healthy individuals. In patient cohorts,
negative ERGs have been reported in between 2.5% and
4.8% of those undergoing electroretinography: in studies
from London, Berlin, Atlanta and Sao Paolo, figures of
4.8% [5], 2.9% [6], 4.0% [7] and 2.5% [8] have been
reported, respectively. Table 3 gives the range of diagnoses
found in these patients. Clearly, the overall prevalence and
proportions in each category depend heavily on local clin-
ical pathways, and the particular patients selected for elec-
trophysiology. In a recent study from an ocular genetics
service from the United Arab Emirates, 6.6% of patients had
negative ERGs [22].
Genetic causes
Inherited retinal diseases classically associated with nega-
tive ERG are CSNB [16, 23] and X-linked retinoschisis
(XLRS) [24, 25]. CSNB has been classically divided elec-
trophysiologically into the rarer “Riggs-type” (where there
is impairment of rod phototransduction resulting in reduced
a-waves) [26] and “Schubert-Bornschein CSNB” [27],
where the a-wave is of normal size. This latter form will be
considered in more detail here; it can further be subdivided
into “complete CSNB” (associated with variants in NYX,
TRPM1, LRIT3, GRM6 and GPR179) and “incomplete
CSNB” (associated with variants in CACNA1F and CABP4)
Fig. 2 Schematic of LA 3
responses in different
conditions with example
causes. A Normal cone system
signalling and normal cone
system ERG. B In conditions
with selective loss of ON bipolar
cell signals, the a-wave is
broadened, and the b-wave
appears to be more sharply
rising. C In conditions with loss
of both ON and OFF bipolar cell
signals (usually due to a
presynaptic lesion), the b-wave
is more attenuated. Green arrows
depict normal transmission; grey
arrows depict impaired
transmission (grey shading
indicates impairment of signal)
(Color figure online).
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[16, 23]. These conditions are associated with negative
dark-adapted ERGs, with normal-sized a-waves and
reduced b-waves. XLRS is associated with variants in RS1,
and patients frequently display negative dark-adapted flash
ERGs with normal-sized a-waves; in some patients the
waveform may not be electronegative, but the b-wave to a-
wave amplitude ratio (b:a ratio) is still subnormal [24].
Figure 3 illustrates ERG responses to standard stimuli in
XLRS and in complete and incomplete CSNB. They are
described in the figure legend and when each condition is
discussed in more detail below. Figure 4 gives the propor-
tions of IRD families (and individuals) in whom disease has
been associated with each of the associated genes [9]. This
was from a large cohort of over 4000 IRD patients from
more than 3000 families managed at a large centre in the
UK (Moorfields Eye Hospital in London), in whom
the genetic diagnosis was known [9]. The upper panels give
proportions from the cohort as a whole and the lower panels
specifically for patients under the age of 18. The proportions
are higher in the lower panels, reflecting the early onset of
these disorders, thus they comprise a larger fraction of the
paediatric cohort. The precise proportions will be affected
by current and historical testing strategies, which might
generate levels of ascertainment bias; however, the figures
give an approximate overview of the proportion of disease
attributable to each gene.
A number of other inherited retinal diseases can be
associated with negative ERGs, usually with subnormal
a-wave amplitudes. In addition, some systemic conditions
can be associated with negative ERGs. Table 1 summarises
much of the range of genetic causes, together with asso-
ciated ERG features.
Three of the genes associated with negative ERGs are X-
linked (NYX, CACNA1F and RS1); Fig. 5 presents a simple
algorithm to identify the likely gene in a male presenting
with a negative ERG and an X-linked family history. For a
more general algorithm to identify the relevant gene in a
male with non-syndromic retinopathy and an X-linked
family history, the reader is referred to Figure 26 in the
review by De Silva et al. [25]. In contrast to several other X-
linked retinopathies, female carriers of pathogenic variants
in NYX, CACNA1F and RS1 (i.e. females with pathogenic
variants on one X chromosome) do not report symptoms or
display signs on fundus examination or imaging.
Complete congenital stationary night blindness
(cCSNB)
Patients with cCSNB usually have reduced visual acuity
and high myopia, together with a history of night blindness.
They may also have nystagmus and strabismus. Mean
logMAR visual acuity has been reported as 0.3 [28] or 0.4
[29] and average refractive error has been reported as
around −7 dioptres [28, 29]. Fundal examination is usually
normal other than myopic changes. Standard ERG testing
shows an undetectable dim flash (DA 0.01) response, and a
negative ERG response to the DA 3 and DA 10 flashes,
with normal-sized a-waves and subnormal b-waves.
Table 3 Range of diagnoses in patients with negative electroretinograms (ERGs) from published large patient cohorts.
Diagnostic categories Patients in each diagnosis category as a proportion (%) of all patients with negative ERGs at each centre
London, UK (n= 128)
(1995–1997)
Berlin, Germany (n= 47)
(1992–2004)
Atlanta, Georgia (n= 50)
(1999–2008)
Sao Paolo, Brazil (n= 41)
(2004–2013)
X-linked retinoschisis 14.8 36.2 14 7.3
CSNB 13.3 12.8 58 2.4
CRAO 10.2 0 4a 0
Birdshot 5.5 0 0 0
Toxic 3.9 2.1 2 0
MAR 3.1 2.1 0 0
Batten 0.8 0 0 0
Inflammatory (unspecified) 2.3 0 2 12.2
Photoreceptor dystrophyb 26.6 27.7 8 58.5
Multisystem atrophy 0 0 2 0
Diabetic retinopathy 0 0 0 4.9
Undiagnosed 19.5 19.1 10 14.6
Numbers of patients with negative ERGs and years reported in each study are given in parentheses.
CSNB congenital stationary night blindness, CRAO central retinal artery occlusion, MAR melanoma-associated retinopathy.
aIn the row corresponding to CRAO, the patients from Atlanta included those with vasculitis as well as vascular occlusions.
bIn patients with negative ERGs attributed to photoreceptor dystrophies, a-waves were also subnormal. This applies also to patients in some of the
other diagnostic categories.
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Fig. 4 Proportions of affected
families (left panels) or
affected individuals
(right panels) from a large
genetically characterised
cohort (of over 4000 inherited
retinal disease patients from
over 3000 families) with
variants in selected genes.
Upper panels (A, B) show data
for the full cohort; lower
panels (C, D) for the subset of
the cohort with individuals
under 18 years.
Fig. 3 Examples of standard ERG responses in different conditions.
A–D Responses to DA 0.01 stimulus (*note the response in iCSNB in
C is schematic; the response from this patient to the dim flash
was contaminated by artefact). E–H responses to DA 10 stimulus.
I–L Responses to LA 30Hz stimulus. M–P Responses to LA 3 stimu-
lus. Responses were recorded with a conductive fibre electrode placed
in the lower conjunctival fornix. The left panels show ERGs from a
healthy subject. Right panels show responses from patients with com-
plete congenital stationary night blindness (cCSNB), incomplete con-
genital stationary night blindness (iCSNB) and X-linked retinoschisis
(XLRS) as labelled. The cCSNB patient had bi-allelic variants in
TRPM1; the iCSNB patient had a hemizygous variant in CACNA1F.
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The 30 Hz flicker might be mildly subnormal and delayed,
and the LA 3 response has a broadened a-wave trough with
sharply rising b-wave (Fig. 3). Associated genes include
NYX (X-linked inheritance) and TRPM1, GRM6, GPR179
and LRIT3 (autosomal recessive inheritance). Pathogenic
variants lead to selective impairment of ON bipolar cell
responses.
Incomplete congenital stationary night blindness
(iCSNB)
Patients with iCSNB also frequently display subnormal
visual acuity and myopia, with nystagmus and strabismus
often present. Nyctalopia, however, is not always reported,
and some patients have photophobia. Mean visual acuity has
been reported to be 0.4–0.5 logMAR, and average refractive
has been reported as ~−8 dioptres [29] or −5 dioptres [28].
The latter study found 22% of patients to be hyperopic and
also found that only 54% reported nyctalopia [28]. X-linked
iCSNB is the more common form, and is associated with
variants in CACNA1F; a rarer, autosomal recessive form of
iCSNB, is associated with bi-allelic variants in CABP4 [16],
and tends to affect vision more severely. Fundal examina-
tion is largely normal other than myopic changes. However,
foveal thinning has been reported in CABP4-associated
disease [30], and inner retinal layer thinning has been
reported in CACNA1F-associated disease [31].
ERG responses to standard stimuli show a subnormal,
but not completely abolished, DA 0.01 response (helping
distinguish from cCSNB). Light-adapted responses are
more severely affected in iCSNB compared with cCSNB: in
iCSNB, the 30 Hz flicker amplitude is severely subnormal,
and may display notched, or bifid, peaks; also, the LA 3
ERG is more markedly subnormal, with a b:a ratio nearer 1,
sometimes below 1.
Both genes encode proteins involved in facilitating
transmission at the photoreceptor synapse. Thus, both ON
and OFF bipolar cells responses are affected. As not all
patients report nyctalopia, “congenital stationary night
blindness” might not be appropriate. The term “cone-rod
synaptic disorder”, originally proposed for disease asso-
ciated with CABP4 variants [32], might be more appro-
priate; this term has been subsequently applied to a range of
monogenic conditions affecting presynaptic processes in
signal transmission at the photoreceptor synapse, including
diseases associated with CACNA1F, CACNA2D4, CABP4
and RIMS2 [33].
X-linked retinoschisis (XLRS)
Patients with XLRS present with central visual impairment
usually in childhood. Between 1 in 15,000 and 1 in 30,000
males are affected [34]. Visual acuity is variable, ranging in
one study from 0 to 1 logMAR equivalent [35], with a more
recent study reporting a range of 0.1 logMAR to no light
perception, with a mean best corrected visual acuity of
around 0.6 logMAR [36]. Retinal examination reveals
schisis at the central macula, best seen on optical coherence
tomography (OCT) imaging. The schisis in some patients
might respond to carbonic anhydrase inhibitors [37, 38].
Fig. 5 Algorithm for establishing likely associated gene in a male patient with a negative ERG and an X-linked pedigree. CSNB congenital
stationary night blindness.
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Patients may also have areas of peripheral schisis and often
show a peripheral retinal sheen. Complications include
retinal detachment and vitreous haemorrhage, both of which
are associated with poorer visual outcomes. Older patients
might show atrophic changes at the macula rather than clear
schisis.
The RS1 gene encodes retinoschisin, expressed and
secreted by photoreceptors. The protein is thought to play
important roles in cellular adhesion and in cell–cell inter-
actions more generally. Roles have also been suggested in
the control of ion gradients and osmolarity [39], as well as
an interaction with channel proteins including CACNA1F
[40], which could help explain some similarities in ERG
phenotypes.
The DA 10 response in XLRS shows a normal-sized a-
wave, with subnormal b-wave. Usually, the waveform is
electronegative. Light-adapted responses are abnormal, with
30 Hz flicker delay, and often subnormal amplitudes.
Patients with more severe variants (including nonsense,
splice-site or frame-shifting variants) have negative DA 10
ERGs and consistently delayed 30 Hz flicker ERGs [24].
Those with milder missense variants might not show LA 30
Hz ERG delay, and the DA 10 ERG might not show a
negative waveform, although the b:a amplitude ratio is
usually subnormal [24]. In children with bilateral foveal
schisis, the ERG is helpful in narrowing the genetic diag-
nosis: a negative waveform in a boy with schisis points to
XLRS; a normal full-field ERG might point to other diag-
noses, including CRB1-associated maculopathy (autosomal
recessive, affecting both sexes) [41–43].
CRX-associated disease
Pathogenic variants in the gene CRX (encoding a tran-
scription factor expressed in photoreceptors) can give rise to
a dominantly inherited retinal dystrophy with variable fea-
tures. This can range from an isolated maculopathy, pre-
senting later in life, to a generalised (often cone-rod) retinal
dystrophy [44]. The ERG phenotype can vary, but there
have been numerous reports of negative ERG waveforms in
this condition [22, 45, 46].
Other IRDs with negative ERGs
Negative ERGs have been reported in other inherited retinal
diseases, but usually with subnormal a-waves. Two largely
stationary conditions that involve night blindness and
negative ERGs with reduced a-waves and fundus abnorm-
alities are Oguchi disease (associated with variants in SAG
or GRK1) [47–51] and fundus albipunctatus (associated
with variants in RDH5) [18, 51]. As explained earlier, the
dark-adapted responses in these conditions largely reflect
the isolated cone system response; thus the mechanism
underlying the negative ERG is quite different from those at
play in XLRS and in complete and incomplete CSNB.
Both Oguchi disease and RDH5-associated fundus albi-
punctatus are autosomal recessive and both sometimes
show improvement in ERG amplitudes following prolonged
(12–24 h) dark adaptation [18]. It should be noted that
variants in all three genes can also be associated with non-
stationary, progressive degenerations. It is possible that
even typical Oguchi disease in adulthood might demon-
strate slow progression [48].
In Oguchi disease, shut-off of light-activated rhodopsin
is impaired (due to defective action of rhodopsin kinase,
encoded by GRK1, or arrestin, encoded by SAG). Thus,
phototransduction remains active, shutting off the outer
segment cGMP-gated current; the rods can no longer
respond to light as the outer segment current is already
abolished. Patients have a bright fundal sheen, which might
disappear after prolonged dark adaptation. The sheen’s
presence or absence has been associated with changes in
OCT appearance of the outer retinal hyper-reflective bands
[52]. After standard dark adaptation, the rods are still not
electrically responsive, and so the DA 10 has a significantly
reduced a-wave. The waveform is also negative as the
response now reflects the dark-adapted cone system
response which is often electronegative. Figure 6 shows
ERGs to standard stimuli from a patient with bi-allelic
variants in GRK1.
In fundus albipunctatus, the retina shows widespread
white dots (these are subretinal deposits when examined
with OCT) [18]. RDH5 encodes a protein involved in the
retinoid cycle which recycles chromophore (this cycle
converting all-trans-retinal ultimately back to 11-cis-retinal
via the retinal pigment epithelium (RPE)). Defects in visual
cycle genes give poor night vision (as the rods are more
affected by deprivation of the light-sensitive photopigment)
and a low fundus autofluorescence signal, as well as sub-
retinal white deposits [53]. In fundus albipunctatus, cone
function is relatively unimpaired (cone responses are less
affected by lower levels of 11-cis-retinal, and cones also
have access to a non-RPE pathway via Muller cells) [54].
The DA ERG again may be reflective of dark-adapted cone
system function (with loss of the larger rod system com-
ponent), and so show subnormal a-waves sometimes with a
negative waveform.
Other diseases affecting rod phototransduction (including
some dominant variants in RHO [55, 56], GNAT1 [57],
PDE6B) [58] can give negative DA ERGs due to similar
mechanisms. Negative ERGs have also been reported in
disease associated with variants in genes including
GUCY2D [45], ABCA4 [59], PRPH2 [60] and CHM [61].
Negative ERGs are uncommon in disease associated with
these genes, and do not usually reflect primary inner retinal
dysfunction. Yang et al. also reported an autosomal
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dominant retinal dystrophy associated with variants in
RAX2, in which electronegative ERGs were consistently
seen [62].
Genetic conditions with systemic involvement
Negative ERGs have been reported in a number of systemic
conditions. Many of these are neurological or neurodegen-
erative conditions, some of which have a metabolic basis:
these include disease associated with bi-allelic variants in
CLN3 (juvenile Batten disease) [63, 64], GNB5-associated
disease [65], WDR73 (Galloway–Mowat syndrome) [66],
Spinocerebellar ataxia-1 [67] (dominantly inherited, asso-
ciated with an expanded trinucleotide repeat in the gene
ATXN1) and others. In the commonest cause of congenital
disorder of glyclosylation, phosphomannomutase-2 defi-
ciency (due to bi-allelic variants in PMM2), negative ERGs
have been reported [68, 69]. Also, in Duchenne and Becker
muscular dystrophies (associated with variants in the X-
linked DMD gene), DA and LA flash ERGs may be nega-
tive or show a subnormal b:a ratio [70].
Of these conditions, juvenile Batten disease is perhaps
the most important to highlight as the visual symptoms
precede the onset of neurological dysfunction, and so these
children may present to the ophthalmologist first. Vision
deteriorates rapidly (symptoms begin between the ages of 4
and 8). Retinal imaging can show a bull’s eye maculopathy
with progressive degeneration. Sometimes these children
are erroneously diagnosed with Stargardt disease (ABCA4-
associated retinopathy), but the visual loss is usually more
profound and rapidly progressive than that seen in Stargardt
disease. ERGs can be electronegative (usually with sub-
normal a-waves) and become undetectable [64]. Neurolo-
gical dysfunction follows and death ensues by early
adulthood. The diagnosis is important to make due to the
important implications on patient and family counselling
(including informing the parents of the risk of having fur-
ther affected children). Variants in CLN3 can also give rise
to a non-syndromic retinal dystrophy (not characterised by a
negative ERG) [71].
Acquired causes
Table 2 summarises some acquired causes of a negative
ERG. In a number of these conditions, the diagnosis can be
Fig. 6 Examples of standard ERG responses in different condi-
tions. A–D Responses to DA 0.01 stimulus. E–H Responses to DA
10 stimulus. I–L Responses to LA 30 Hz stimulus. M–P Responses to
LA 3 stimulus. The left panels show ERGs from a healthy subject.
Middle panels show responses from patients with Oguchi disease
(associated with bi-allelic variants in GRK1) and prior quinine toxicity,
as labelled. In the right-most panels, the black traces show responses
from a patient with vitamin A deficiency (VAD); red traces show
normalisation of DA responses following vitamin A replacement (by
intramuscular injection) (Color figure online).
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made with retinal imaging or specific blood tests (or cer-
tain features in the clinical history). However, in MAR, the
ERG findings are very specific [4, 17], and can lead to this
important diagnosis, despite retinal imaging being near
normal or showing non-specific changes. Thus, MAR will
be discussed first.
Melanoma-associated retinopathy (MAR)
This is a subset of autoimmune paraneoplastic retinopathy.
In 1984, Ripps et al. [72]. reported night blindness and
ERG findings resembling those seen in CSNB in a patient
with a history of cutaneous melanoma. They attributed the
retinopathy to the patient’s vincristine treatment. Four
years later, Berson and Lessell [4] reported a patient with
similar ERG findings and a history of melanoma, and
concluded that the retinopathy in their patient, and in the
previously reported patient of Ripps et al., represented a
paraneoplastic phenomenon. Interestingly, in the same
year, DuBois et al. [73] reported a negative ERG in a
patient with migraine, and in a later letter, published in
1991 (in response to correspondence regarding their case)
[74], they reported that the patient had informed them 2
years later that he had just been treated for an axillary
cutaneous and lymph node melanoma; their earlier report
was perhaps the first description of a patient in whom the
visual symptoms and ERG findings preceded the diagnosis
of melanoma.
The ERG phenotype in MAR is usually very similar to
that seen in complete CSNB (shown in Fig. 4), reflecting
selective loss of ON bipolar responses. In 2011 [17, 75], it
was shown that autoantibodies to TRPM1 (expressed by
ON bipolar cells, and encoded by one of the genes asso-
ciated with cCSNB) [76] were present in the serum of
patients with MAR, hence explaining the ERG findings.
These antibodies have also been found in some patients
with non-melanoma cancers, including lung [75] and
ovarian [77] cancer. In patients with recent onset symptoms
(which can include nyctalopia, blurring of vision, photopsia
and visual field loss) and such ERG responses, investiga-
tions should be conducted for melanoma or other cancer. In
patients with a known diagnosis of melanoma, onset of the
retinopathy might prompt referral to oncologists to inves-
tigate for recurrence or metastasis (in the case reported by
Berson and Lessell, the retinopathy preceded the diagnosis
of metastasis) [4], although active retinopathy might not
necessarily indicate systemic recurrence. Whilst melanoma
treatment has improved dramatically in recent years, visual
dysfunction due to MAR can be more challenging to treat.
There have been recent reports of success of local intrao-
cular steroid treatments [78, 79] in improving or stabilising
vision.
Cancer-associated retinopathy (CAR)
Unlike MAR, ERG findings in CAR are more variable, but
can include electronegative ERGs. Such ERGs have been
reported in paraneoplastic retinopathy associated with a
range of cancers including lung and ovarian cancer [75, 77].
Thus in patients with such ERGs, and no obvious other
cause, a systemic survey for cancer may be initiated.
Autoantibodies reported in non-melanoma paraneoplastic
retinopathies include antibodies to TRPM1, recoverin and
others; however, several autoantibodies can also be found in
non-paraneoplastic cases (see below) [80].
Vascular causes
Retinal ischaemia or infarction secondary to retinovascular
disease can lead to a negative ERG. This includes central
retinal artery occlusion, ischaemic central retinal vein
occlusion (CRVO) and any widespread retinal ischaemia,
for example due to retinal vasculitis or extensive diabetic
vascular disease. As the photoreceptors are supplied by the
choroidal circulation, these are spared, and so inner retinal
layer dysfunction and loss ensues. With modern retinal
imaging techniques (OCT, fluorescein angiography, OCT
angiography), ERGs are not usually required for the diag-
nosis of these conditions, although they can be helpful in
showing the extent of inner retinal dysfunction. In a study
of patients with diabetic vitreous haemorrhage undergoing
vitrectomy, a negative pre-operative ERG was associated
with poorer post-operative visual acuity, compared with
those without a negative ERG [81].
Toxicity due to systemically administered agents
Retinopathy characterised by a negative ERG waveform,
can occur following administration or overdose of various
agents, including quinine, vigabatrin and methanol (the
latter found in antifreeze and some home-brewed alcoholic
drinks); possible mechanisms have been discussed in a
previous review [3]. The diagnosis should be apparent in
the clinical and medication history (although direct ques-
tioning may be needed). Figure 6 shows ERG findings in a
patient with longstanding quinine toxicity. Quinine has
been used as an antimalarial treatment, and also for night
cramps. In the past, it was used as an abortifacient. In the
acute phase of quinine toxicity, patients can experience
symptoms including severe visual loss, nausea, vomiting,
headache and tinnitus. Fundal imaging may show retinal
oedema with vascular attenuation and ERGs can show
global reduction in amplitude. With time, vision may
improve and a negative ERG is seen that persists [82]. OCT
shows persistent inner retinal layer thinning [82].
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Direct ocular toxicity: siderosis
Intraocular iron foreign bodies can lead to retinal degen-
eration. They should be suspected particularly following
potential exposure to high velocity penetrating injuries
(when the point of entry may not be easily apparent).
The inner retinal layers appear to be vulnerable to
degeneration earlier than the outer retina, hence a negative
ERG can result [83]. Early removal is advised to
preserve or improve vision. With time, the a-wave
also becomes subnormal, and the ERG can become
undetectable.
Autoimmune non-paraneoplastic retinopathies
Autoimmune retinopathies [84] are presumed to result from
the action of autoantibodies to retinal antigens. They are a
group of disorders with features whose variability pre-
sumably relates to numerous factors including identity of
the particular autoantigens, the level (titre) of auto-
antibodies, and the degree to which the blood-retinal barrier
is intact. Presentation is variable, usually with symptoms of
photopsia or visual field defects, but can also include nyc-
talopia or photoaversion. Presentation can often be asym-
metric or unilateral (with the second eye sometimes affected
after an interval). Fundal examination may be near normal
or show pigmentary abnormalities, but multimodal retinal
imaging including fundus autofluorescence and OCT may
reveal changes. ERGs are usually abnormal, and this can
include negative ERGs. A review of cases with unilateral
electronegative ERGs (that were not due to vascular
occlusion or Birdshot chorioretinopathy) frequently found
evidence of inflammatory changes in the affected eye, and
the authors postulated an autoimmune aetiology [85].
Recently a clinical entity of acute unilateral inner retinal
dysfunction has been described: the aetiology is unclear,
and it is possible that inflammatory or autoimmune
processes play a role [86].
Although testing is conducted for autoantibodies, their
significance is not always certain, as autoantibodies to
retinal antigens can be found in healthy individuals [87]
and in patients with other retinal diseases, where their
presence may be incidental or may be contributory to
secondary destructive processes. Some patients with a
diagnosis of autoimmune retinopathy can be observed
initially, and treatment (which can include steroids and
immunosuppressive agents) initiated in cases of definite
progression; the aim of treatment is to stabilise or improve
visual symptoms, or delay progression, but success is
variable. An important concern is to exclude systemic
malignancy as paraneoplastic disease represents a subset
of autoimmune retinopathy, and presentation can be
similar to non-paraneoplastic autoimmune retinopathy.
Other inflammatory causes
Inflammatory posterior uveitic conditions can give rise to a
negative ERG. A well-established association is with
Birdshot chorioretinopathy (associated with HLA-A29 ser-
otype). In these patients a variety of ERG abnormalities can
be found, most consistently delay in the LA 30 Hz ERG
peak time (which can be used to guide treatment) [88, 89].
Negative ERGs can be seen, and may resolve with treat-
ment. The pathophysiology might relate to inflammatory
mechanisms affecting post-phototransduction processes or
the inner retinal vasculitis that some patients display. In one
report, a markedly supranormal a-wave was seen, with
normalisation of amplitude following treatment [88]. Other
inflammatory vasculitides, particularly those leading to
widespread retinovascular occlusion, can also generate
negative ERGs due to inner retinal ischaemia or infarction.
Infective conditions, including tuberculosis, can also give
rise to occlusive vasculitis [90].
Nutritional: Vitamin A deficiency (VAD)
Vitamin A deficiency leads to nyctalopia, but when pro-
longed and established, can also affect cone-mediated cen-
tral and photopic vision. Other symptoms and signs may
include dry skin and dry mouth, conjunctival Bitot spots
(accumulations of keratin) and white dots on fundus
examination (that are subretinal in location on OCT).
Dietary deficiency occurs globally, but is rare in the
developed world. VAD in developed countries can occur
with reduced intestinal absorption, which can occur with
previous small bowel disease or small bowel resection, or
with liver disease (where loss of bile-production leads to
reduced absorption of fat-soluble vitamins A, D, E and K).
In cases of acquired nyctalopia, particularly if there is
relevant medical history, VAD should be suspected and
vitamin A levels checked. Vitamin A replacement in those
cases where intestinal absorption is poor may need to be
parenterally administered, for example by intramuscular
injection.
As the light-sensitive chromophore in photoreceptors,
11-cis-retinal, is derived from vitamin A, VAD affects the
sensitivity of photoreceptors. Rods are more numerous and
more susceptible to loss of sensitivity when deprived of
chromophore. Cone function is largely intact (in initial
stages at least), and so night blindness is the main visual
symptom. ERGs show impaired rod function, yielding
subnormal DA ERG amplitudes, but relatively normal LA
ERG amplitudes. The DA 3 and DA 10 ERGs will show
subnormal a-waves, but may also show a negative wave-
form, as this may reflect the dark-adapted cone system
response as discussed above [21]. Figure 6 shows ERGs in a
patient with VAD. Prior to Vitamin A replacement (black
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Table 4 Clinical approach to diagnosis of patients with negative ERGs.
Features in patient history
Ocular history • CSNB patients have stationary, congenital visual impairment, and are associated with myopia. XLRS
usually presents in childhood. Rapidly progressive visual loss aged 4–8 can be seen in juvenile Batten
disease. Acquired conditions usually have much later onset of symptoms
• More acute/subacute onset of symptoms in adult (e.g. photopsia, night blindness) could reflect autoimmune
(including paraneoplastic) disorders or inflammatory/vascular disorders. Some genetic conditions can
present in adulthood
• History of IOFB or penetrating injury may point towards siderosis
General medical history • Specific neurological/neuromuscular/metabolic systemic diagnoses
• Medication history to include quinine, vigabatrin (and methanol)
• Known diagnosis or symptoms suggestive of cancer or melanoma
• Dietary insufficiency or intestinal or liver disease that could result in VAD
Family history • Male with X-linked pedigree suggests X-linked genes (RS1, NYX, CACNA1F)
• Other generations not affected in autosomal recessive diseases (unless pseudodominance/consanguinity)
• Dominant family history in CRX-related disease
Features on non-invasive retinal imaging
Colour fundus imaging, OCT, AF • Myopic changes in CSNB
• Schisis in XLRS (sometimes macular outer retinal atrophy in adult)
• Bull’s eye maculopathy and progressive degeneration in CLN3-associated Batten disease
• Range of changes possible in CRX-related retinopathy, but symmetric
• Sheen in Oguchi disease; small white dots in fundus albipunctatus and in VAD
• Outer retinal abnormalities, non-specific thinning, pigmentary changes possible in autoimmune and
inflammatory retinopathies, often asymmetric
• Typical pale depigmented lesions in Birdshot chorioretinopathy. Inflammatory conditions may have cystoid
macular oedema
• Inner retinal OCT hyper-reflectivity and swelling in CRAO followed by loss of inner retinal layers over
weeks months. Widespread haemorrhages in CRVO
• Evidence of trauma or IOFB in siderosis
FFA, ICG • FFA can delineate ischaemia/leakage in retinovascular/inflammatory disease
• ICG can help in choroidal diseases; hypofluorescent lesions in Birdshot
Features relating to ERGs
Are the abnormalities bilateral
and symmetric?
• Genetic diseases, systemic drug toxicities, and Vitamin A deficiency should give symmetric abnormalities
• Ocular siderosis and central retinovascular occlusions are usually unilateral
• Paraneoplastic, inflammatory, autoimmune conditions may be unilateral or bilateral, and can be asymmetric
Is the DA 10 a-wave normal-
sized or subnormal?
• Normal-sized in CSNB, XLRS
• Normal-sized in CRAO and CRVO and certain drug toxicities
• May be normal-sized in MAR, but can be variable in other inflammatory and autoimmune retinopathies
(including CAR)
• Can be normal or subnormal in CRX-related disease
• A-wave usually subnormal in fundus albipunctatus, Oguchi disease, Batten disease and other diseases
affecting photoreceptors
• A-wave subnormal in VAD
What is the shape of the LA
responses?
• Shape may reflect selective ON pathway dysfunction (cCSNB, MAR) or combined ON and OFF
dysfunction (other conditions)—see Figs. 2 and 3
• LA response may be normal when cone system function normal (and DA responses reflect intact cone
function)
Features in the history and findings in non-invasive clinical investigations (including retinal imaging and ERGs) of patients that narrow the
differential diagnosis. The following invasive investigations can be helpful in selected cases: fundus fluorescein angiography can delineate extent
of ischaemia or leakage in retinovascular or inflammatory disease; indocyanine green angiography can further characterise choroidal disease,
including demonstration of hypofluorescent lesions in Birdshot chorioretinopathy that are not evident clinically. Further investigations (including
non-ocular imaging, blood tests, genetic investigations) are guided by the findings above.
IOFB intraocular foreign body.
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traces), the DA 0.01 ERG is near undetectable, and the
DA 10 ERG shows a subnormal a-wave and a negative
waveform. The LA 30 Hz and LA 3 ERGs are normal. After
replacement (red traces) the dark-adapted responses nor-
malise (with increase in the DA 10 a-wave and b-wave),
whilst the light-adapted responses remain unchanged.
Clinical approach to patients
Given the range of conditions associated with negative
ERGs, the clinical approach to such patients will seek to
elicit key features to narrow the differential diagnosis.
Electrophysiological features to consider when observing a
negative ERG response to the DA 3 or DA 10 stimuli
include the following: whether the abnormalities are in both
eyes or just one (and if bilateral, whether they are sym-
metric); whether the a-wave is of normal size or subnormal;
the findings in the DA 0.01 response (whether it is unde-
tectable or subnormal, helping distinguish complete and
incomplete CSNB) and the shape of the LA responses. The
patient’s clinical ocular and medical history, medications,
family history and results of investigations (retinal imaging
and genetic investigations) are also pertinent. Table 4
summarises features of the clinical assessment. Further
investigations (including systemic imaging, blood tests and
gene panel testing) are guided by the findings of this
assessment.
Additional ERG protocols
This review has focused on the ISCEV standard full-field
ERG protocols [1, 2]. Additional non-standard protocols
can be helpful in further clarifying the nature of retinal
dysfunction. In particular, the photopic ON–OFF ERG can
be used to help distinguish between conditions in which
there is selective impairment of ON responses or combined
impairment of ON and OFF responses [10]. A long flash
(150–200 ms in duration) is delivered in the presence of a
rod-saturating background so that responses to onset and
offset of the stimulus can be separated. Conditions such as
cCSNB and MAR may be expected to selectively impair the
ON response. Many of the other conditions may affect both
responses. In retinopathy associated with previous quinine
toxicity, the ON response is markedly impaired, but there
may be relative preservation of the early component of
the OFF response, followed by a plateau [10]. In those
conditions where cone system function is normal, these
responses are also likely to be normal.
Figure 7 shows such responses recorded with a portable
device from a healthy individual: a negative a-wave fol-
lowed by a positive b-wave is seen in response to stimulus
onset, and a positive-going response, termed the d-wave, in
response to stimulus offset. The lower panel shows the
response from a patient with complete CSNB secondary to
bi-allelic variants in TRPM1. Here, the positive b-wave
response to stimulus onset is attenuated, but the response to
stimulus offset appears spared.
Further insights
Currents shaping the a-wave trough
Several previous studies have applied mathematical models
of rod photocurrent responses [91] to fit the ERG [92–94],
and have assumed that the bright flash dark-adapted a-wave
trough, and the immediate recovery following the trough, is
due to the intrusion of depolarising currents in ON bipolar
cells. Loss of ON bipolar cell depolarisation would then be
expected to result in an increased a-wave amplitude.
However, this appears not to be the case: patients with
abolition of ON bipolar cell responses due to genetic con-
ditions (for example complete CSNB) do not show
Fig. 7 Responses to ON–OFF ERG stimuli. The stimulus is a long
(150 ms) white flash delivered on a white background. The grey rec-
tangle at the bottom shows the duration of the stimulus. A shows
responses from a healthy individual. B shows responses from a patient
with complete congenital stationary night blindness (bi-allelic variants
in TRPM1). The patient’s responses show selective loss of the b-wave
in response to stimulus onset. ERGs were recorded with a portable
ERG device (RETeval, LKC Technologies, Gaithersburg, MD, USA).
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supernormal a-waves to standard flash strengths, nor do
patients with loss of inner retina following vascular occlu-
sion. The initial recovery (repolarisation) after the a-wave
trough persists (see Fig. 3). Animal models of CSNB [95],
or primate recordings after pharmacological manipulation to
remove post-receptoral responses [96], yield similar results.
Robson and Frishman [11] have shown that the a-wave
trough in response to such flash strengths (and more strong
Fig. 8 Retinal expression by cell type of genes associated with
negative ERGs. Data plot expression levels found in the second
supplementary table (“Dataset EV2”) from the study of Lukowski
et al. (2019). This is following canonical correlation analysis to correct
for batch effects. The clusters have been reordered to group cell types,
and bars representing the same cell type have been given the same
colour.
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flashes) is instead likely to be shaped by current flows in
parts of the photoreceptor proximal to the outer segment (in
the inner segment or outer nuclear layer), and their model of
these current flows appears to explain much of the available
experimental and patient data. In some inflammatory con-
ditions, a supernormal a-wave has been observed [88], and
the origin of this is unclear. It is possible that the site of
primary pathology is located within the photoreceptor rather
than, or in addition to, the inner retina (post-receptoral
layers). Modification of previous assumptions and applica-
tion of newer mathematical models to patient waveforms
might yield novel non-invasive quantitative assessments of
retinal function in these disorders, together with newer
insights into pathophysiology.
Insights into genetic diseases from single-cell
transcriptome data
Although the genetic basis for several inherited causes of
negative ERGs is now known, precise mechanisms of visual
impairment remain to be elucidated in many of these condi-
tions. Single-cell transcriptome data are now becoming
increasingly available, and will help us understand patterns of
cellular expression. A recent study reported single-cell RNA
sequencing of more than 20,000 retinal cells from three
human donors [12]. Several transcriptionally distinct clusters
were found and the relative expression levels in different cell
types are given in their supplementary material; their second
supplementary dataset gives an exhaustive list of genes and
expression levels following correction of batch effects by
canonical correlation analysis [12]. Figure 8 plots these data
for particular genes that can be associated with negative
ERGs. Bars representing the same broad neuronal cell type
have been given the same colour, and the clusters have been
reordered so that clusters of the same broad cell type are
together.
Several expected and unexpected findings emerge. The
genes associated with complete CSNB are all almost
exclusively expressed by bipolar cells as expected (NYX,
TRPM1, GRM6, GPR179). Interestingly, LRIT3, although
associated with a similar ERG phenotype, is expressed in
photoreceptors and Muller cells with very little relative
expression in bipolar cells. Thus, it might be predicted that
presynaptic expression by photoreceptors is important in
particular in rod to ON bipolar cell transmission. A recent
murine study suggested that this is the case: presynaptic
expression of LRIT3 transsynaptically organises the post-
synaptic glutamate signalling complex, which contains
TRPM1 [97]. With regard to incomplete CSNB genes,
although CACNA1F and CABP4 both give rise to similar
ERG phenotypes, Fig. 8 shows that the former is expressed
in both photoreceptors and bipolar cells at comparative
levels, whilst the latter is expressed very strongly in
photoreceptors. It is possible that the bipolar cell expression
of CACNA1F might mean that pathogenic variants in this
gene give rise to additional impairment of transmission
between bipolar cells and ganglion cells. A recent study of
retinal layer thicknesses in CACNA1F-associated disease
reported evidence of inner retinal layer thinning that
appeared not explicable by the degree of myopia [31].
CLN3 is expressed in multiple cell types, with bipolar cells
showing strongest expression. This might explain the pat-
tern of ERG degeneration with initial greater attenuation of
the b-wave followed by loss of both a-wave and b-wave
[64]. It should be noted that Fig. 8 only depicts expression
in the neural retina; for some genes (such as RDH5), the
RPE expression is likely to be relevant to disease.
Future treatments
For most IRDs, there remain no medical or surgical treat-
ments that can bring about lasting improvement of vision.
A number of the non-syndromic IRDs in this review
fortunately show relative stability, but some can be pro-
gressive. For RS1-associated disease, trials of intravitreally
administered gene-replacement therapy [98] are being
conducted (ClinicalTrials.gov Identifiers: NCT02317887
and NCT02416622). For CLN3-associated disease, a phase
1/2 open-label, single-dose, dose-escalation clinical trial of
intrathecal gene therapy (ClinicalTrials.gov Identifier:
NCT03770572) is listed, but has not commenced recruit-
ment. Pharmacological treatments are also being trialled for
this condition [99]. Full results of these trials will be eagerly
awaited.
With respect to acquired disease, treatments for inflam-
matory retinopathies are improving with newer immunomo-
dulatory agents available. In patients with melanoma, survival
has improved in recent years with newer treatments, including
immune checkpoint inhibitors (though these treatments have
been associated with ocular side effects). Treatment of MAR,
and autoimmune paraneoplastic and non-paraneoplastic reti-
nopathy in general, remains challenging. As mentioned
above, there have been anecdotal reports of success with local
intraocular steroid in MAR [78, 79].
Conclusions
Whilst progress has been made in the understanding of many
of these conditions, several unanswered questions remain,
both for genetic and acquired disorders (for example, the
variability in phenotype in CRX-associated disease even
within families, or why some patients develop autoimmune
paraneoplastic and non-paraneoplastic retinopathies whilst
others do not, even with similar cancers). The electronegative
ERG is an important finding. In genetic disease, this can
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narrow the differential in terms of likely associated genes. In
the past, genetic testing proceeded gene by gene, whereas
now it is common to start with simultaneous testing of large
gene panels by next generation sequencing or even to com-
mence with whole genome sequencing. The latter strategy
frequently returns numerous variants of uncertain sig-
nificance. Precise evaluation or re-evaluation of the pheno-
type, including by electrophysiology, can help determine
which variants are relevant. In the context of acquired disease,
the negative ERG can point to particular diagnoses. In some
cases of MAR, the visual dysfunction and electro-
physiological findings might precede the melanoma diag-
nosis, and initiating the search for the tumour could
potentially bring about early detection and treatment, with a
possible influence on survival.
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